NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Alpha Cognition Inc. Common Stock (ACOG) Stock Analysis

Alpha Cognition Inc. Common Stock (ACOG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACOG

$9.52

+$0.31 (+3.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACOG with… →

ACOG Key Statistics

As of Sep 4, 2026
Trading
Open
$9.22
Previous Close
$9.21
Day's Range
9.10–9.54
52-Week Range
4.50–10.14
Volume
45.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.24
Valuation
Market Cap
$207.33M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.59
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.96
Financials (FY)
Revenue (FY)
$10.22M
Net Income (FY)
−$20.67M
Profit marginThe share of revenue left as profit after all costs and taxes.
−137.70%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.78M
1-Year Return
+14.01%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
106.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACOG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+46.46%
2025+10.36%
2024 (partial year)+3.33%

As of September 4, 2026.

ACOG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.22M−$20.67M−202.2%
2024$0.00−$14.79M—
2023$0.00−$13.76M—
2022$0.00−$12.11M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.22M$8.30M−$22.58M−$20.67M−202.2%
2024$0.00$0.00−$11.55M−$14.79M—
2023$0.00—−$9.62M−$13.76M—
2022$0.00—−$13.47M−$12.11M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACOG Valuation vs Biotechnology Median

Median of 656 stocks
MetricACOGBiotechnology medianvs median
P/S ratio13.5915.2611% below
Profit margin−137.70%0.00%137.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alpha Cognition Inc. Common Stock (ACOG) is capitalised at $207.33M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 71 employees.

Over the past 52 weeks the price has ranged from $4.50 to $10.14. The most recent close on file for ACOG is $9.52, dated September 4, 2026. That is +$0.31 (+3.37%) against the previous close. The latest close sits 111.56% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $10.22M. The same year closed with a net loss of $20.67M. The reported profit margin is −137.7%. That is 137.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.96.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $10.22M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 13.59 times revenue. On price-to-sales that is 10.99% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.24. Daily returns over the trailing 1 year annualize to a volatility of 67%. Over the trailing twelve months the price has returned +14.01%. The stored price history starts on November 12, 2024, and the total return since then is +67.02%.

Growth & Income

The record shows no dividend for ACOG.

The record holds one complete calendar year, 2025, which returned +10.36%. So far in 2026 the price is +46.46%.

Peer Comparison

Alpha Cognition Inc. Common Stock (ACOG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alpha Cognition Inc. Common Stock ACOG $207.33M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Alpha Cognition Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Alpha Cognition Inc. Common Stock

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Visit website →